Consolidated Basic Cancer Research Program

描述(申请人提供)：20世纪60年代初，S大学的科学家开始致力于癌症研究。在维托里奥·德芬迪博士、芭芭拉·诺尔斯博士和卡洛·M·克罗齐博士的领导下，肿瘤病毒学、癌症发生和分子生物学取得了重大进展。由于对癌症研究的日益重视，Wistar获得了癌症中心支持拨款(CCSG)，并于1972年被国家癌症研究所(NCI)指定为联邦指定的癌症中心，专门从事基础研究。该研究所40多年来一直得到NCI的持续资助，在癌症遗传学、癌症生物学、肿瘤免疫学和病毒学方面取得了重大进展。癌症中心从NCI获得了11,582,210美元的总资金，相当于联邦同行审查资金总额的50%以上，证明了该中心对癌症的关注。癌症中心的组织是为了发展和支持癌症中心成员、研究项目和共享设施。癌症中心的每个实验室都由一名首席研究员领导，该研究员在该研究所有一个积极的研究计划。癌症中心由一名主任和两名副主任领导。考夫曼博士是癌症中心的主任，对癌症中心的空间、财政资源、任命和工作人员职位拥有最终的控制权。弗兰克·J·劳舍尔三世博士和米哈德·赫林博士担任癌症中心的副主任。Rauscher博士的主要职责是促进基础科学研究，而Herlyn博士则负责翻译研究领域的领导工作。 在上一次筹资期间，癌症中心取得了重大进展，招募了12名科学家，翻新了癌症中心的实验室空间，对共享设施中的新仪器进行了广泛的翻新和投资，并开发了资源和扩大实验室设施的计划。最重要的是，我们在癌症遗传学、癌症生物学、计算生物学和肿瘤免疫学等领域取得了重大科学进展。

DESCRIPTION (provided by applicant): In the early 1960's Wistar's scientists began to devote increasing efforts to cancer research. Significant advances were made in tumor virology, carcinogenesis, and molecular biology, led by Drs. Vittorio Defendi, Barbara Knowles, and Carlo M. Croce. In recognition of this increased focus on cancer research, Wistar received a Cancer Center Support Grant (CCSG) and was designated by the National Cancer Institute (NCI) as a federally designated Cancer Center in 1972, specializing in basic research. The Institute has had over 40 years of continuous funding from the NCI with a history of significant advances in cancer genetics, cancer biology, and tumor immunology and virology. The Cancer Center receives $11,582,210 of total funding from the NCI, amounting to over 50% of total federal peer reviewed funding, attesting to the cancer focus of the Center. The Cancer Center is organized to develop and support Cancer Center members, research programs, and the Shared Facilities. Each laboratory in the Cancer Center is headed by a principal investigator who has an active research program at the Institute. The Cancer Center is headed by a Director and two Deputy Directors. Dr. Kaufman is the Director of the Cancer Center and has ultimate control of space, financial resources, appointments, and staff positions in the Cancer Center. Drs. Frank J. Rauscher III and Meenhard Herlyn serve as the Cancer Center's Deputy Directors. Dr. Rauscher's primary responsibility is promotion of basic science research, while Dr. Herlyn provides leadership in the area of translational research. The Cancer Center has made significant progress over the course of the last funding period with recruitment of 12 scientists, renovation of Cancer Center laboratory space, extensive renovation and investment in new instrumentation in shared facilities, and development of resources and plans to expand laboratory facilities. Most importantly, we have made major scientific advances in the fields of cancer genetics, cancer biology, computational biology, and tumor immunology.